Clinical trials: Diabetic Complication
Chronic Pain, Diabetic Neuropathies
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing…
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Trial name
- NCT01939366
- Testing
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg
- Where
- 82 sites in United States, Austria and 6 more
- Volunteers
- 699 people
- Sponsor
- Tris Pharma, Inc.
Diabetic Retinopathy
A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus
This study is to evaluate the clinical performance of VeriSee DR for DR screening from color fundus photography images in patients with diabetes mellitus.
- Trial name
- NCT04160988
- Where
- Taiwan
- Volunteers
- 703 people
- Sponsor
- Acer Being Health Inc.
Diabetic Foot Ulcer
GrafixPL PRIME Evaluation Case Study
The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and GrafixPL…
- Trial name
- NCT03742440
- Testing
- GrafixPL PRIME
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetic Retinopathy
Sirolimus to Treat Diabetic Macular Edema
Objective: Diabetic macular edema (DME) is a frequent manifestation of diabetic retinopathy, a leading cause of blindness in the United States. The only proven treatment for DME is laser photocoagulation.
- Trial name
- SDME (NCT00711490)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Nephropathies, Coronary Artery Disease
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Despite improvements during the past 20 years in blood glucose and blood pressure control, diabetic kidney disease remains one of the most important causes of health problems in patients with diabetes.
- Trial name
- NCT02017171
- Testing
- Allopurinol
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 530 people
- Sponsor
- Alessandro Doria
Lower Leg Wound
A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention
A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention
- Trial name
- WoundWand (NCT01924806)
- Testing
- WoundWand™ Debridement Device, Standard of Care sharp debridement
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Smith & Nephew, Inc.
Diabetes Mellitus, Chronic Kidney Disease
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with…
- Conditions
- Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
- Trial name
- NCT00552409
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Diabetic Foot Ulcer
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial…
- Trial name
- NCT00765063
- Testing
- Fragmin
- Where
- 27 sites in Austria, Belgium and 12 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Chronic Kidney Disease
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function.
- Trial name
- NCT04736628
- Testing
- Avenciguat
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.
- Trial name
- FEENICS (NCT00662831)
- Testing
- Fragmin/ Dalteparin Sodium
- Where
- 63 sites in Austria, Belgium and 15 more
- Volunteers
- 276 people
- Sponsor
- Pfizer
Diabetic Autonomic Neuropathy
An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes.
- Trial name
- NCT00116207
- Testing
- ORAL ANTIOXIDANT
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes, Diabetic Nephropathy
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1…
- Conditions
- Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- Alk-UA (NCT02502071)
- Testing
- sodium bicarbonate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Kidney Disease
A Phase 2b Diabetic Kidney Disease Study
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
- Trial name
- NCT04170543
- Testing
- MEDI3506, Dapagliflozin
- Where
- 97 sites in United States, Argentina and 5 more
- Volunteers
- 609 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Nephropathy
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality in T1D is diabetic kidney disease (DKD).
- Conditions
- Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes
- Trial name
- CASPER (NCT03618420)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Diabetic Foot Ulcer, Amputation
Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers
Chronic foot ulcers occurring among diabetic patients are difficult to heal. The frequent elderly age with co-morbidities, vascular insufficiencies, peripheral neuropathies and super imposed infections, all contribute towards the…
- Trial name
- NCT00393510
- Testing
- TCM
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Diabetic Macular Edema
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan…
- Trial name
- DAVE (NCT01552408)
- Testing
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- David M. Brown, M.D.
Painful Diabetic Neuropathy
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable…
- Trial name
- SENZA-PDN (NCT03228420)
- Testing
- Senza HF10 Therapy, CMM
- Where
- 4 sites in United States
- Volunteers
- 430 people
- Sponsor
- Nevro Corp